Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Warren’s bill, dubbed the Affordable Drug Manufacturing Act, would require HHS to publicly manufacture generic drugs “in cases where the market has failed,” and “[strengthen] the market for the long term by jump-starting competition.”
Specifically, the office would be authorized to manufacture a generic drug in a case in which no company is currently manufacturing the product; a case in which only 1 or 2 companies produce the drug, and the price has spiked or the drug is in shortage; or a case in which only 1 or 2 companies produce the drug, the price has created a barrier to patient access, and the World Health Organization has designated the medication as an essential medicine.
“In market after market, competition is dying as a handful of giant companies spend millions to rig the rules, insulate themselves from accountability, and line their pockets at the expense of American families,” said Warren in a statement. “The solution here is not to replace markets, but to fix them. The Affordable Drug Manufacturing Act will introduce more competition into the prescription drug market and bring down prices for consumers.”
The price of insulin has entered the spotlight recently as it is becoming increasingly less affordable, particularly for young adults. Since 2012, the price has more than doubled in the United States. The bill would attempt to address this by requiring the office to begin public production of insulin within 1 year.
Within 1 year of the bill’s enactment, the office will be required to manufacture at least 15 applicable drugs. Additionally, no later than 3 years after the bill is enacted, the office will be required to manufacture or enter into contracts with entities for the manufacturing of at least 25 applicable products.
The introduction of the bill comes on the heels of a letter sent by Warren to Republican colleagues calling for hearings on the recent reports of alleged price-fixing by generic manufacturers in the start of January 2019.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.